Literature DB >> 9066036

The synthesis of Streptococcus pneumoniae polysaccharide-tetanus toxoid conjugates and the effect of chain length on immunogenicity.

C A Laferrière1, R K Sood, J M de Muys, F Michon, H J Jennings.   

Abstract

To study the relationship between length of pneumococcal polysaccharide and immunologic performance in rabbits we took well defined fragments of the capsular polysaccharides of S. pneumoniae types 3, 6A, 18C, 19F and 23F and pneumococcal C-polysaccharide and linked them terminally by reductive amination to tetanus toxoid. Contrary to other reports we found little variation in antibody titers with increasing length. In general the opsonophagocytic titers determined using activated HL60 cells and rabbit peritoneal cells correlated well with the antibody titers except for that of type 3, which despite the presence of high polysaccharide antibody titers gave unexpectedly low opsonophagocytic titers. The C-polysaccharide-conjugate was also immunogenic when injected in both rabbits and mice but gave low opsonophagocytic titers. It was demonstrated that opsonophagocytosis was solely dependent on the presence of phosphoryl choline-specific antibody and that the induction of these antibodies was species dependent.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9066036     DOI: 10.1016/s0264-410x(96)00148-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1.

Authors:  V Pozsgay; C Chu; L Pannell; J Wolfe; J B Robbins; R Schneerson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

2.  Thermodynamics and density of binding of a panel of antibodies to high-molecular-weight capsular polysaccharides.

Authors:  Shannon L Harris; Philip Fernsten
Journal:  Clin Vaccine Immunol       Date:  2008-11-12

3.  Streptococcus pneumoniae type 14 polysaccharide-conjugate vaccines: length stabilization of opsonophagocytic conformational polysaccharide epitopes.

Authors:  C A Laferriere; R K Sood; J M de Muys; F Michon; H J Jennings
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

4.  A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection.

Authors:  Sharavathi Guddehalli Parameswarappa; Katrin Reppe; Andreas Geissner; Petra Ménová; Subramanian Govindan; Adam D J Calow; Annette Wahlbrink; Markus W Weishaupt; Bopanna Ponnappa Monnanda; Roland Lawrence Bell; Liise-Anne Pirofski; Norbert Suttorp; Leif Erik Sander; Martin Witzenrath; Claney Lebev Pereira; Chakkumkal Anish; Peter H Seeberger
Journal:  Cell Chem Biol       Date:  2016-11-03       Impact factor: 8.116

5.  Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy.

Authors:  M R Wessels; L C Paoletti; H K Guttormsen; F Michon; A J D'Ambra; D L Kasper
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

6.  Synthetic polysaccharide type 3-related di-, tri-, and tetrasaccharide-CRM(197) conjugates induce protection against Streptococcus pneumoniae type 3 in mice.

Authors:  B Benaissa-Trouw; D J Lefeber; J P Kamerling; J F Vliegenthart; K Kraaijeveld; H Snippe
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

7.  Outer membrane proteins as a carrier for detoxified lipooligosaccharide conjugate vaccines for nontypeable Haemophilus influenzae.

Authors:  T H Wu; X X Gu
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

8.  Experimental design to optimize an Haemophilus influenzae type b conjugate vaccine made with hydrazide-derivatized tetanus toxoid.

Authors:  Craig Laferriere; Neil Ravenscroft; Seanette Wilson; Jill Combrink; Lizelle Gordon; Jean Petre
Journal:  Glycoconj J       Date:  2011-08-19       Impact factor: 2.916

9.  Protective immunity of microsphere-based mucosal vaccines against lethal intranasal challenge with Streptococcus pneumoniae.

Authors:  S Y Seong; N H Cho; I C Kwon; S Y Jeong
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

10.  Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide.

Authors:  Richard Malley; Amit Srivastava; Marc Lipsitch; Claudette M Thompson; Claire Watkins; Arthur Tzianabos; Porter W Anderson
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.